Innovative Peptide Therapy Reawakens Dormant Immune Cells to Reverse Chronic Airway Inflammation in Allergic Asthma

Scientists use the KQS-1 peptide to reactivate dormant immune cells, successfully reversing asthma inflammation in mice via epigenetic reprogramming.

By: AXL Media

Published: Apr 1, 2026, 4:53 AM EDT

Source: Information for this report was sourced from Rockefeller University Press

New Evidence for Immune Re-education in Asthma

A collaborative study involving the Henan Academy of Innovations in Medical Science and Shenzhen University has provided a proof-of-principle for a novel asthma treatment. Published in Life Science Alliance, the research suggests that the chronic inflammation typical of allergic asthma is driven by a "senescence-like" state in regulatory T cells (Tregs). Rather than these cells being permanently lost, they appear to enter a dormant phase where they stop performing their anti-inflammatory duties. The study demonstrates that these cells can be strategically "re-educated" to regain their protective functions.

The Pathophysiology of Treg Dysfunction

Allergic asthma is traditionally understood as an imbalance between pro-inflammatory cells and the Tregs responsible for keeping them in check. When Tregs fail, the result is bronchial hyperreactivity and excessive mucus production. However, the exact molecular reason for this failure has remained elusive until now. Using human samples from asthmatic patients, the research team confirmed that these dysfunctional cells lose the ability to express two vital components: the transcription factor FOXP3 and the signaling molecule IL-10, both of which are essential for suppressing lung inflammation.

Restoring Genetic Activity via Dectin-1

The researchers focused on a specific surface protein called the Dectin-1 receptor, which acts as a gateway for cellular reprogramming. By applying a small peptide known as KQS-1, the team was able to engage this receptor and trigger metabolic and epigenetic changes within the dormant cells. This process effectively "reawakened" the genes responsible for FOXP3 and IL-10 production. According to co-senior author Liguo Li, this engagement leads to a sustained restoration of the cells' immunoregulatory capacity, suggesting the change is durable rather than a temporary fix.